Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
Asymptomatic Infections
COVID-19
/ epidemiology
COVID-19 Vaccines
/ genetics
Cohort Studies
Female
Humans
Immunity, Humoral
Immunization, Secondary
Infection Control
/ statistics & numerical data
Male
Middle Aged
Patient Acuity
SARS-CoV-2
/ genetics
Treatment Outcome
United Kingdom
/ epidemiology
Vaccination
Young Adult
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
21
06
2021
accepted:
14
09
2021
pubmed:
1
10
2021
medline:
15
12
2021
entrez:
30
9
2021
Statut:
ppublish
Résumé
The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF
Identifiants
pubmed: 34588689
doi: 10.1038/s41591-021-01540-1
pii: 10.1038/s41591-021-01540-1
pmc: PMC8604724
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2032-2040Subventions
Organisme : Wellcome Trust
ID : 211153/Z/18/Z
Pays : United Kingdom
Organisme : DH | National Institute for Health Research (NIHR)
ID : NA
Investigateurs
Syed Adlou
(S)
Lauren Allen
(L)
Brian Angus
(B)
Rachel Anslow
(R)
Marie-Claude Asselin
(MC)
Natalie Baker
(N)
Philip Baker
(P)
Thomas Barlow
(T)
Amy Beveridge
(A)
Kevin R Bewley
(KR)
Phillip Brown
(P)
Emily Brunt
(E)
Karen R Buttigieg
(KR)
Susana Camara
(S)
Sue Charlton
(S)
Emily Chiplin
(E)
Paola Cicconi
(P)
Elizabeth A Clutterbuck
(EA)
Andrea M Collins
(AM)
Naomi S Coombes
(NS)
Sue Ann Costa Clemens
(SAC)
Melanie Davison
(M)
Tesfaye Demissie
(T)
Tanya Dinesh
(T)
Alexander D Douglas
(AD)
Christopher J A Duncan
(CJA)
Katherine R W Emary
(KRW)
Katie J Ewer
(KJ)
Sally Felle
(S)
Daniela M Ferreira
(DM)
Adam Finn
(A)
Pedro M Folegatti
(PM)
Ross Fothergill
(R)
Sara Fraser
(S)
Harriet Garlant
(H)
Laura Gatcombe
(L)
Kerry J Godwin
(KJ)
Anna L Goodman
(AL)
Christopher A Green
(CA)
Bassam Hallis
(B)
Thomas C Hart
(TC)
Paul T Heath
(PT)
Helen Hill
(H)
Adrian V S Hill
(AVS)
Daniel Jenkin
(D)
Mwila Kasanyinga
(M)
Simon Kerridge
(S)
Chanice Knight
(C)
Stephanie Leung
(S)
Vincenzo Libri
(V)
Patrick J Lillie
(PJ)
Spyridoula Marinou
(S)
Joanna McGlashan
(J)
Alastair C McGregor
(AC)
Lorna McInroy
(L)
Angela M Minassian
(AM)
Yama F Mujadidi
(YF)
Elizabeth J Penn
(EJ)
Christos J Petropoulos
(CJ)
Katrina M Pollock
(KM)
Pamela C Proud
(PC)
Samuel Provstgaard-Morys
(S)
Durga Rajapaska
(D)
Maheshi N Ramasamy
(MN)
Katherine Sanders
(K)
Imam Shaik
(I)
Nisha Singh
(N)
Andrew Smith
(A)
Matthew D Snape
(MD)
Rinn Song
(R)
Sonu Shrestha
(S)
Rebecca K Sutherland
(RK)
Emma C Thomson
(EC)
David P J Turner
(DPJ)
Alice Webb-Bridges
(A)
Terri Wrin
(T)
Christopher J Williams
(CJ)
Informations de copyright
© 2021. The Author(s).
Références
MMWR Morb Mortal Wkly Rep. 2021 May 07;70(18):674-679
pubmed: 33956782
Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
JAMA. 2021 Jul 6;326(1):35-45
pubmed: 34037666
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Science. 2020 Nov 27;370(6520):1110-1115
pubmed: 33037066
Environmetrics. 2013 Mar;24(2):132-142
pubmed: 23504271
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
Lancet. 2021 Apr 10;397(10282):1351-1362
pubmed: 33798499
Nat Med. 2021 Aug;27(8):1370-1378
pubmed: 34108716
Nat Med. 2021 Feb;27(2):270-278
pubmed: 33335323
J Hyg (Lond). 1985 Aug;95(1):173-89
pubmed: 2991366
Infect Dis Poverty. 2020 Nov 25;9(1):161
pubmed: 33239109
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Environ Health Perspect. 2004 Dec;112(17):1691-6
pubmed: 15579415
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
Stat Med. 2019 Jan 30;38(2):210-220
pubmed: 30207407
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Nat Med. 2021 Feb;27(2):279-288
pubmed: 33335322
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288661
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
Nat Commun. 2021 Oct 7;12(1):5868
pubmed: 34620866
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
J Infect Dis. 2007 Nov 1;196(9):1304-12
pubmed: 17922394
J Infect Dis. 2004 Jul 15;190(2):373-8
pubmed: 15216475
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Clin Immunol. 2020 Aug;217:108486
pubmed: 32479985
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246